NEW YORK, March 9, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
There are many sanguine predictions made about the molecular diagnostics but to be useful, context is needed. How can companies sort out what is effective and what is not in this market? For over a decade, Kalorama Information's lead diagnostics analyst Shara Rosen, R.T., MBA has reviewed the molecular diagnostics market. A lot has changed, and a lot has stayed the same. There is intense competition but also opportunities for entrants in some areas. This report The World Market for Molecular Diagnostics: Potential and Reality, What's Hot and What's Not provides current market data for business planning but also goes beyond the numbers to fully assess what is going on in the market.
What are the important developments in the market? Who are the small innovators in this industry and how are the big players reacting to them? Which developments are "hot" - response from providers and payors and which trends have not caught on? In this report, Rosen provides answers to these questions.
The Rewards, Pitfalls and Competition of This High Potential MarketAs we enter the second decade of the 21st century the investment in molecular biology, in bioinformatics, in disease management research and the unraveling of the human genome is bearing fruit. Almost every day the discovery of new molecular markers for cancer, cardiac disease, diabetes, arthritis, neurological diseases and psychiatric conditions are announced.
This title, The World Market for Molecular Diagnostics -Potential and Reality, What's Hot and What's Not provides a detailed examination of molecular testing today. Among the data points the report provides are the following:
More and more laboratories offer complex panels of tests that help physicians evaluate disease risk and make therapeutic decisions. Government and private healthcare payors have recognized the value of new molecular tools and have agreed to pay for them.
This renewed interest in IVDs in general and more particularly in molecular diagnostics has lead to the commercialization of a number of technological tools that make more sensitive and specific tests possible. Some of these technological innovations include: cost-effective, multiplexed testing platforms coupled with high-powered software capabilities. In addition analyses using saliva, urine, and blood instead of biopsied tissue make for more patient-friendly test systems.
Copyright©2010 PR Newswire.
All rights reserved